Aptahem hosted a webinar where CEO Mikael Lindstam provided an overview of Aptahem's strategic direction, ongoing preparations for a planned U.S. listing, and recent key regulatory developments.
The webinar is available via the link below:
https://gumlet.tv/watch/6902846960d267cdc081c34f/
Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
Epost: ml@aptahem.com
Aptahem AB (APTA) is a clinical stage biotechnology company that develops RNA-based pharmaceuticals for the treatment of acute, life-threatening conditions in which a combination of coagulation, inflammation and tissue damage are involved. The company's lead candidate, Apta-1, is currently in early clinical phase. Apta-1 has in preclinical studies, by its anti-thrombotic, immunomodulating and tissue repairing characteristics, shown very positive and promising results as treatment for sepsis and critical conditions associated with sepsis. For more information, please visit www.aptahem.com.